The Neuron Study (MAD)

Study Objective:

• The study medication is a potential new treatment for various neurological conditions, including neurodegeneration (diseases that affect the nerve cells of the brain) and glaucoma.
• The study will provide crucial information on the safety, tolerability, and effectiveness of the study medication in humans, paving the way for future clinical use.
• The study medication is administered as an oral tablet. It is designed to prevent degeneration. Participants in MAD cohorts will receive 1 dose twice a day for 10 days.

Importance of Treatment:

• If successful the study medication could become a valuable therapy for neurodegenerative conditions, which currently lack effective treatments.
• The study medication works by inhibiting a specific naturally occurring protein, which may protect nerve fibers from degeneration, potentially benefiting patients with various neurodegenerative diseases, including ALS.
  

Clinical Trial Details:

• An independent ethics committee has approved this clinical trial.
• Participants will be reimbursed for their time.
  

Call us on 1800 243 733 to discuss your eligibility today!